Clinipace, a global technology-driven clinical research organization (CRO), announced today that on October 26th, 2009 the company closed its acquisition of Worldwide Clinical Research, Inc. (WWCR), a Midwest-based CRO specializing in the management of clinical studies for biotechnology and pharmaceutical companies. With the acquisition, Clinipace has changed its name to Clinipace Worldwide.
Combined, the companies have managed over 70 contract research projects conducted globally at almost 3,000 sites with 100,000 patients. With specific expertise in oncology, among other therapeutic areas, the company will offer fully-integrated technology-based clinical research solutions and services to growth-oriented and mid-tier biopharmaceutical and medical device firms.
WWCR currently provides core clinical operations functionality including monitoring, site management, and project management. These services will now be augmented by Clinipace’s focus on technology-driven clinical research solutions to provide clients with full-service, global research services that result in greater trial visibility, more project control, and lower costs.
With the addition of more than 30 employees, the company headquarters will remain in Research Triangle Park, NC with additional domestic operations in Overland Park, KS, and South American operations based in Sao Paulo, Brazil, Buenos Aires, Argentina, and Lima, Peru. Clinipace has experienced triple digit growth over the past 12 months and is expected to continue to hire in all locations throughout 2010 to support its growing CRO business.
“Having honed our expertise on electronic data management services, we felt it was critical to expand both our clinical operations expertise and global presence in order to support our growth,” said Jeff Williams, Clinipace CEO. “As one of the industry’s most trusted CROs, WWCR’s reliable service, global access to enrolling sites, and program-level therapeutic experience will be a natural complement to our existing research model and global expansion strategy.